<DOC>
	<DOCNO>NCT02763579</DOCNO>
	<brief_summary>This randomize , Phase I/III , multicenter , double-blinded , placebo-controlled study design evaluate safety efficacy atezolizumab ( anti-programmed death ligand 1 [ anti-PD-L1 ] ) combination carboplatin plus ( + ) etoposide compare treatment placebo + carboplatin + etoposide treatment-naive participant extensive-stage small cell lung cancer ( ES-SCLC ) . Participants randomize 1:1 ratio receive either atezolizumab + carboplatin + etoposide placebo + carboplatin + etoposide 21 day-cycles 4 cycle induction phase follow maintenance atezolizumab placebo disease progression ( PD ) assess investigator use Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST v1.1 ) . Treatment continue persistent radiographic PD symptomatic deterioration .</brief_summary>
	<brief_title>A Study Carboplatin Plus Etoposide With Without Atezolizumab Participants With Untreated Extensive-Stage Small Cell Lung Cancer IMpower133</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants 18 year age old Histologically cytologically confirm ESSCLC ( per Veterans Administration Lung Study Group [ VALG ] stag system ) No prior treatment ESSCLC ECOG performance status 0 1 Measurable disease , define RECIST v1.1 Adequate hematologic end organ function Active untreated central nervous system ( CNS ) metastasis determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation Malignancies SCLC within 5 year prior randomization , exception negligible risk metastasis death treat expect curative outcome Pregnant lactate woman History autoimmune disease History idiopathic pulmonary fibrosis , organize pneumonia , drug induce pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest Computed Tomography ( CT ) scan . History radiation pneumonitis radiation field ( fibrosis ) permit . Positive test Human Immunodeficiency Virus ( HIV ) Active hepatitis B hepatitis C Severe infection time enrollment Significant cardiovascular disease Prior treatment cluster differentiation 137 ( CD137 ) agonists immune checkpoint blockade therapy , antiPD1 , antiPDL1 therapeutic antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>